Obesity confers an increased incidence and poorer clinical prognosis in over ten cancer types. Paradoxically, obesity provides protection from poor outcomes in lung cancer.
Abstract
Obesity confers an increased incidence and poorer clinical prognosis in over ten cancer types. Paradoxically, obesity provides protection from poor outcomes in lung cancer.
Mechanisms for the obesity-cancer links are not fully elucidated, with altered glucose metabolism being a promising candidate. Using 18 Obesity, currently affecting 35-40% of adults in the United States 1 , is correlated with an increased incidence and poorer clinical outcomes in more than ten different types of cancer 2 . The mechanisms underlying the obesity-associated cancer risk are currently not well defined, but altered glucose metabolism is characteristic of both increased body mass index (BMI) 3 and cancer 4, 5, 6, 7 . Distinct metabolic mechanisms exist between tumor types at the cellular level 8, 9 . Epidemiologic data allude to differences at the population level as obesity is detrimental in many cases 10 but seemingly protective in lung cancer 11 .
As a tumor's avidity for glucose underlies the use of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), we used PET/CT images to examine tumor glucose metabolism in patients with four cancer types: head and neck squamous cell carcinoma (HNSCC) 12 , soft tissue sarcoma (STS) 13 , breast cancer 14, 15 , and non-small cell lung cancer (NSCLC) 16, 17, 18, 19, 20, 21 .
Utilizing the National Cancer Institute-funded open-source database, The Cancer Imaging Archive (TCIA) 22 , we performed a retrospective cross-sectional analysis to examine tumor glucose uptake (TGU) in patients with obesity-associated and nonobesity associated cancers.
All patients with an 18 F-FDG PET and CT scan, sex, height, and weight available from TCIA were studied. All subjects provided informed consent in accordance with each site's Institutional Review Board. If multiple images were available, the first PET/CT scan was used to minimize effects of therapy on the tumor. Power analyses for correlation with β=0.20, and α=0.05 necessitated a minimum of 29 patients, thus the four tumor types with 29 unique patient PET/CTs were analyzed. Clinical parameters such as tumor stage and medications were unavailable.
PET and CT images were loaded into ImageJ with an open source PET-CT
Viewer 23 , and tissues were analyzed with a fixed-volume approach 24 . Briefly, fixedvolume spheres were drawn to measure maximal glucose uptake in tumor, skeletal muscle (deltoid, infraspinatus, or quadriceps), liver, spleen, and subcutaneous and supraclavicular adipose tissue. Standardized uptake values (SUV) were calculated 25 .
Because in obese patients, BMI alone is related to SUV, the Janhamastian Formula was used to calculate and correct for estimated lean body mass (LBM) 26 . The primary endpoint was LBM-corrected SUV (SUL) (in g/mL) of tumors, as related to BMI (in kg/m 2 ). Maximal SUL was chosen to avoid issues from partial volume effects.
Two-sided Pearson correlations were used to measure BMI versus TGU. A twoway ANOVA was used with Tukey's multiple comparisons test to examine differences in TGU across cancer types, between tissues, and between sexes. Data were analyzed in GraphPad Prism 7.0. REMARK reporting guidelines were used where applicable 27 .
Statistical significance was determined as p < 0.05. Sex, height, weight, BMI, estimated LBM, and estimated percent body fat (%BF) were reported (Supplementary Table 1 ). Among 97 women and 91 men, BMI ranged from 17.4-49.3 kg/m 2 (Mean: 27.7, SD= 5.1) and %BF ranged from 11.1-55.5%. Many STS PET/CT images were taken from waist down, and some breast cancer images were taken from above L3, thus estimated %fat could not be calculated using the L3 vertebral level method 28 .
PET/CT data revealed a positive correlation between BMI and TGU in breast cancer (r=0.36, p=0.02), yet a negative correlation in NSCLC (r=-0.26, p=0.048) ( Figure   1 ). In these cohorts, we calculated Target to Background Ratio (TBR), where tumor SUV was divided by SUV in the descending aorta. Pearson correlations between TBR and BMI for breast cancer (r=0.25, p=0.13) and NSCLC (r=-0.34, p<0.001) were calculated. No statistically significant correlations were seen in HNSCC (r=0.06, p=0.71) nor STS (r=0.23, p=0.11) ( Figure 1 ). HNSCC TGU was higher than in breast cancer (p<0.001), STS (p<0.001), and NSCLC (p=0.04) ( Figure 2 ). STS TGU was higher than breast cancer TGU (p=0.002) ( Figure 2 ). This may be due to a higher proportion of men in the HNSCC group (17.1% female) and STS group (52.9% female) as compared to the 100% female breast cancer cohort, as men had higher glucose uptake in nearly all tissues (Supplementary Table 2 ). This observation likely reflects men's higher metabolic rate 29 .
Tumor SUV intensity has been used as a surrogate for breast cancer time to progression 30 . In the PERCIST Guidelines 31 Our results demonstrate no statistically significant correlation of BMI with TGU in STS 35 , but previous reports suggest a weak link between STS severity and obesity 36, 37 .
We detected no correlation between BMI and SUV in HNSCC, supporting a prior study that demonstrates that even in the setting of diabetes, obesity per se is not correlated with HNSCC risk 38 . Though our results cannot confirm that TGU is altered by obesity, this study provides a potential explanation for obesity's role in cancer risk and progression in patients with a wide range of BMIs. Yet, the limited sample size may have reduced the power of our study.
The influence of health and treatment status could not be studied here. Chronic hyperglycemia, higher circulating insulin levels, increased inflammation, elevated glucocorticoids, and more related mechanisms on systemic glucose metabolism in obese patients may impact tumor progression 39 . These and other obesity-related factors may reduce TGU in NSCLC and reduce risk 40 and improve survival 41 across all stages and histological subtypes of lung cancer 42 . Chemotherapy can increase or decrease tumor and immune cell FDG uptake 43 . Anti-diabetic therapies (metformin 44 , SGLT2 inhbitors 45 ) may also reduce TGU in multiple cancers.
In summary, tumor glucose metabolism was related to BMI in a detrimental and protective manner in breast and lung cancer, respectively. Publicly available PET/CT images were acquired through the NCI's TCIA, and analyzed in free open source software, demonstrating the growing utility of shared resources in oncology. Though limited by the availability of clinical information, we highlighted a putative physiological mechanism for obesity's impact on the aggressiveness of multiple tumor types.
Prospective studies should be designed to include clinical parameters to better characterize dysregulated glucose metabolism. A two-way ANOVA was performed, with Tukey's test for multiple comparisons to compare tissue glucose uptake between cancer types. All tests were two-sided, and statistical significance was determined as p < 0.05. 
